Issuu on Google+

Letter from the Chairman, CEO and President

We are pleased to present the Sabin Vaccine Institute (Sabin) 2012 annual report. The past year marked the 20th year of Sabin’s operations, which have included groundbreaking programs in vaccine development and advocacy projects helping the world’s poor gain access to much-needed vaccines and medicine. Our performance over the past two decades is a testament to the spirit of innovation, partnership and strategic leadership that Sabin has brought to the global health community. Through this work, we are uniquely positioned to deliver on the promise of a healthier future for billions of people. During the past year, we advanced the effort to achieve universal access to vaccines. Our Vaccine Advocacy and Education program, led by Dr. Ciro de Quadros, launched the International Association of Immunization Managers, the first global professional association for immunization program managers. We became a core partner in the new ProVac International Working Group, which is expanding an innovative model to help countries decide when to introduce new vaccines. Our Sustainable Immunization Financing program grew to 18 pilot countries, scaling up our efforts to strengthen national sources of funding for immunization programs. In addition, we spearheaded advocacy initiatives to reduce the burden of typhoid and paratyphoid fevers, dengue fever, meningococcal disease, pneumococcal disease, rotavirus, and rubella and congenital rubella syndrome, among others. Under the leadership of Dr. Peter Hotez, the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) is at the forefront of developing and testing new vaccines to prevent neglected tropical diseases (NTDs). In 2012, our human hookworm vaccine candidate, Na-GST-1, entered clinical trials

in the United States; concurrently, in an ongoing clinical trial in Brazil, no safety issues were observed when healthy adults who had not been exposed to hookworm received the vaccine. We began a toxicology study for our schistosomiasis vaccine candidate, in preparation for filing an investigational new drug application in 2013. Additionally, we expanded our portfolio with new vaccine projects focused on Chagas disease, leishmaniasis and severe acute respiratory syndrome (SARS). The Global Network for Neglected Tropical Diseases, headed by Dr. Neeraj Mistry, also had a pivotal year as we worked with our international partners to expand and strengthen NTD control programs. In 2012, we mobilized funding to deliver life-changing NTD treatments to more than 90 million people. With support from philanthropist Dr. Gary Michelson, we announced the appointment of four new NTD Special Envoys who raise the visibility of the effects of debilitating NTDs among heads of state and senior government officials. Furthermore, we launched an exciting new advocacy campaign called END7, which works in partnership with celebrities and entertainment and media companies to promote the NTD cause to millions of people. Our work over the past 20 years has reinforced our conviction that good health is essential to enabling communities to break free from poverty. As we face the challenges and opportunities of the next decade, we look forward to continuing our collaboration with partners and supporters from around the world. We thank you for your commitment to Sabin Vaccine Institute’s vision of healthy, prosperous communities everywhere.

Morton P. Hyman Chairman

Michael W. Marine, Ambassador (Ret.) CEO

Peter J. Hotez, M.D., Ph.D. President 3

F_SABIN1009_AnnualReport_mech.indd 3

4/14/14 4:51 PM


F sabin1009 annualreport mech single3